Liver cirrhosis - Nursing Case Study
Pathophysiology
• Primary mechanism: Hepatocyte injury and death lead to chronic inflammation, triggering the activation of hepatic stellate cells. These cells transform into myofibroblasts, producing excess extracellular matrix and collagen, resulting in fibrosis and architectural distortion of the liver.
• Secondary mechanism: Progressive fibrosis disrupts normal hepatic blood flow, causing increased portal vein pressure (portal hypertension). This leads to complications such as varices and ascites, as blood seeks alternative pathways.
• Key complication: Impaired liver function due to fibrosis results in decreased synthesis of vital proteins and detoxification processes, contributing to symptoms like jaundice, coagulopathy, and hepatic encephalopathy.
Patient Profile
Demographics:
58-year-old male, construction worker
History:
• Key past medical history: Chronic alcohol use disorder, Hepatitis C infection, hypertension
• Current medications: Furosemide, Spironolactone, Propranolol
• Allergies: Penicillin
Current Presentation:
• Chief complaint: Abdominal swelling and discomfort
• Key symptoms: Ascites, jaundice, fatigue, mild confusion, peripheral edema
• Vital signs: Blood pressure 140/90 mmHg, heart rate 95 bpm, respiratory rate 18 breaths per minute, temperature 37.2°C
Section 1
As the patient's condition is further evaluated, initial laboratory tests reveal several critical findings contributing to his clinical picture. The liver function tests show elevated levels of bilirubin at 3.5 mg/dL, ALT at 90 U/L, and AST at 120 U/L, indicating ongoing liver injury and compromised detoxification capacity. Additionally, albumin levels are low at 2.8 g/dL, reflecting impaired protein synthesis, while the INR is elevated at 1.8, suggesting coagulopathy due to decreased production of clotting factors. The complete blood count shows mild thrombocytopenia with a platelet count of 110,000/µL, likely secondary to splenic sequestration from portal hypertension.
Further imaging studies, including an abdominal ultrasound, confirm the presence of significant ascites and reveal splenomegaly. Doppler ultrasound also suggests signs of portal hypertension with reversal of flow in the portal vein. This aligns with the patient's symptoms of abdominal swelling and discomfort, as well as the peripheral edema observed during the physical examination. Notably, the presence of mild confusion suggests the onset of hepatic encephalopathy, a complication that requires close monitoring and management to prevent further cerebral compromise.
In response to these findings, the clinical team considers adjustments to the current management plan. The diuretic regimen may need optimization to better control ascites while monitoring electrolyte balance, particularly potassium levels given the use of both Furosemide and Spironolactone. Additionally, lactulose may be introduced to address hepatic encephalopathy by reducing ammonia levels. Frequent monitoring of mental status and laboratory values will be crucial in guiding treatment and anticipating any further complications, such as potential variceal bleeding, given the high risk associated with portal hypertension. The care team remains vigilant, ready to adapt the intervention strategy as the patient's condition evolves.
Section 2
As the clinical team implements the updated management plan, the patient's condition is closely monitored for any changes. After initiating lactulose therapy to manage hepatic encephalopathy, the nursing staff observes an improvement in the patient's mental status, with reduced confusion and increased orientation to time and place. However, during a routine assessment, the patient reports increased fatigue and noticeable bruising on his arms and legs, which raises concerns about possible worsening coagulopathy. Vital signs are stable, with blood pressure at 110/70 mmHg, heart rate at 88 bpm, respiratory rate at 18 breaths per minute, and temperature at 98.6°F, but the patient exhibits mild tachycardia.
In the context of the patient's ongoing treatment with diuretics, a follow-up set of laboratory tests is performed to ensure electrolyte balance and evaluate any further changes in liver function and coagulation status. The results reveal a decrease in potassium levels to 3.2 mmol/L, necessitating a reassessment of the diuretic regimen to prevent hypokalemia, which could complicate cardiac function. Additionally, the INR has risen slightly to 2.0, indicating a further decline in coagulation capacity, warranting closer monitoring for signs of bleeding and potential adjustment of anticoagulation considerations.
The care team decides to supplement potassium and adjust the diuretic dosages while continuing to monitor the patient's coagulation profile and mental status. This nuanced approach aims to balance the management of ascites and hepatic encephalopathy while minimizing the risk of bleeding complications. The clinical reasoning centers on integrating the dynamic laboratory findings with the patient's evolving clinical presentation, anticipating potential complications, and preparing to intervene promptly should new issues arise. This comprehensive strategy underscores the importance of vigilance and adaptability in managing complex cases of liver cirrhosis with multiple interrelated complications.
Section 3
As the clinical team continues to monitor the patient's condition, a change in the patient's status prompts further evaluation. Despite the initial improvement in mental status with lactulose therapy, the patient begins to exhibit increasing abdominal discomfort and distention. Upon physical examination, the nurse notes a significant increase in abdominal girth, and the patient reports feeling more bloated and experiencing reduced appetite. The clinical team suspects worsening ascites, a common complication in cirrhosis, which necessitates an immediate ultrasound to assess fluid accumulation.
The ultrasound confirms the presence of increased ascitic fluid, and the decision is made to perform a therapeutic paracentesis to relieve symptoms and prevent further complications such as spontaneous bacterial peritonitis (SBP). During the procedure, 2 liters of straw-colored fluid are removed, providing the patient with significant symptomatic relief. Samples of the ascitic fluid are sent for analysis to check for infection, given the risk of SBP in cirrhotic patients. Meanwhile, laboratory tests reveal a further decrease in albumin levels to 2.8 g/dL, highlighting the need to reconsider nutritional support and possibly albumin infusion to help maintain oncotic pressure and prevent further fluid shifts.
This unfolding situation requires the team to balance the management of ascites while continuing to address the patient's coagulopathy and electrolyte disturbances. The multidisciplinary approach involves adjusting the medication regimen to include an albumin infusion post-paracentesis and ensuring adequate dietary intake to support liver function and overall health. This careful coordination of care aims to prevent additional complications and optimize the patient's quality of life as the team remains vigilant in monitoring for any new developments.
Section 4
Following the therapeutic paracentesis, the patient initially experiences relief from abdominal discomfort and improved appetite. However, over the next 48 hours, the patient's condition exhibits a concerning change. The patient becomes increasingly lethargic and disoriented, which prompts the clinical team to perform a thorough reassessment. Vital signs indicate a blood pressure of 95/60 mmHg, heart rate of 110 beats per minute, respirations of 22 per minute, and a temperature of 101.2°F. The patient's skin appears jaundiced, and scleral icterus is noted. With these changes, the team suspects a possible new complication, such as spontaneous bacterial peritonitis (SBP), given the patient's immunocompromised state and recent paracentesis.
Laboratory results reveal a marked elevation in the patient's white blood cell count at 15,000/µL, with a significant shift to the left, indicating a possible bacterial infection. The ascitic fluid analysis returns with a polymorphonuclear leukocyte (PMN) count of 320 cells/mm³, confirming the diagnosis of SBP. Additionally, the patient's serum sodium is critically low at 125 mEq/L, suggesting worsening hyponatremia, which may be contributing to the neurological symptoms. In response, the clinical team initiates broad-spectrum intravenous antibiotics to target the suspected infection and carefully considers the patient's fluid status to address the hyponatremia without exacerbating the ascites.
This development necessitates a careful reassessment of the patient's overall management plan. The team must navigate the complex interplay of treating the infection, managing fluid and electrolyte imbalances, and adjusting the patient's nutritional and medication regimen to support hepatic function. Close monitoring of the patient's mental status, vital signs, and laboratory parameters will be crucial in guiding therapy adjustments and preventing further deterioration. The clinical team's coordinated efforts remain focused on stabilizing the patient's condition and mitigating the risk of additional liver-related complications.
Section 5
Response to Interventions
Following the initiation of broad-spectrum intravenous antibiotics, the clinical team observes the patient closely for signs of improvement or further decline. Over the next 24 hours, the patient's fever begins to subside, with the temperature dropping to 99.5°F, indicating a partial response to the antibiotics. However, the patient's mental status remains concerning, as lethargy and disorientation persist. The healthcare team, recognizing the potential impact of severe hyponatremia on neurological function, prioritizes correcting the sodium imbalance cautiously to prevent central pontine myelinolysis.
Fluid management is adjusted to address the low serum sodium while avoiding fluid overload. The team opts for a slow correction strategy using hypertonic saline under strict monitoring, ensuring that serum sodium levels rise no more than 6-8 mEq/L per day. Regular assessment of neurological status, serum electrolytes, and urine output is conducted to evaluate the effectiveness of the intervention. Despite these efforts, the patient's sodium level only modestly improves to 128 mEq/L, necessitating continued vigilance and possible adjustments to the treatment plan.
In conjunction with addressing the infection and electrolyte disturbances, the team evaluates the patient's nutritional status. Given the patient's improved appetite post-paracentesis, efforts are made to provide a diet rich in essential nutrients while being mindful of protein intake to prevent hepatic encephalopathy. The patient is started on a hepatic-friendly diet with adequate carbohydrates and adjusted protein levels, supplemented by vitamins and minerals to support overall recovery. Through these combined interventions, the team aims to stabilize the patient's condition, reduce the risk of further complications, and set the stage for gradual improvement in liver function and overall health.